[1]马则胜.慢性阻塞性肺疾病药物治疗研究[J].医学信息,2020,33(02):47-49.[doi:10.3969/j.issn.1006-1959.2020.02.013]
　MA Ze-sheng.Study on Drug Treatment of Chronic Obstructive Pulmonary Disease[J].Medical Information,2020,33(02):47-49.[doi:10.3969/j.issn.1006-1959.2020.02.013]
点击复制

慢性阻塞性肺疾病药物治疗研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年02期
页码:
47-49
栏目:
综述
出版日期:
2020-01-15

文章信息/Info

Title:
Study on Drug Treatment of Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2020）02-0047-03
作者:
马则胜
（天津市武清区第二人民医院急诊科，天津 301700）
Author(s):
MA Ze-sheng
(Department of Emergency,the Second People’s Hospital of Wuqing District,Tianjin 301700,China)
关键词:
慢性阻塞性肺疾病; 药物治疗; 致病机制
Keywords:
Chronic obstructive pulmonary disease; Drug therapy; Pathogenic mechanism
分类号:
R563.3
DOI:
10.3969/j.issn.1006-1959.2020.02.013
文献标志码:
A
摘要:
慢性阻塞性肺疾病（COPD）是一种最常见的慢性气道疾病，其起病较为缓慢、病程较长、病情迁延难愈，在早期没有自觉症状。伴随着病情的不断发展，可出现终身不愈的慢性咳嗽，并在气道、肺血管、肺实质内出现炎症应激反应，也会并发慢性呼吸衰竭、自发性气胸、慢性肺源性心脏病等疾病，严重影响患者正常工作与生活质量。目前，临床针对COPD的治疗仍以药物为主，药物治疗的目标在于改善临床症状、提高生活质量，延缓或减弱肺功能减退，预防和治疗并发症，提高存活率，避免或减少用药副作用。因此，寻求合适的药物治疗方案来满足COPD患者的临床治疗需求对于改善患者预后具有十分重要意义。本文通过对COPD致病机制、药物治疗方案作一综述，旨在为临床治疗该疾病提供参考依据。
Abstract:
Chronic obstructive pulmonary disease (COPD) is one of the most common chronic airway diseases. Its onset is relatively slow, its duration is long, its condition is difficult to heal, and it has no conscious symptoms at an early stage. With the continuous development of the disease, a chronic cough that never heals, and inflammatory stress reactions in the airways, pulmonary blood vessels, and parenchyma can occur. Chronic respiratory failure, spontaneous pneumothorax, and chronic pulmonary heart disease can also occur and other diseases, which seriously affect patients’ normal work and quality of life. At present, the treatment of COPD in the clinic is still mainly drugs. The goals of drug treatment are to improve clinical symptoms, improve quality of life, delay or weaken pulmonary function, prevent and treat complications, improve survival rate, and avoid or reduce side effects of medication. Therefore, it is very important to find a suitable drug treatment plan to meet the clinical treatment needs of patients with COPD. This article reviews the pathogenesis of COPD and drug treatment programs, and aims to provide a reference for clinical treatment of the disease.

参考文献/References:

[1]肖亚军.炎症效应导致慢性阻塞性肺疾病相关性肾损伤的实验研究[D].西南医科大学,2016. [2]刘江伟,赵立,朱丽华,等.气流受限不完全可逆的慢性阻塞性肺疾病患者容量和流速变化与肺通气功能障碍严重程度分级的关系[J].中国医科大学学报,2016,45(9):805-808. [3]侯刚.不同表型慢性阻塞性肺疾病的介入呼吸病学治疗[J].临床内科杂志,2018,35(11):736-739. [4]Eapen MS,Myers S,Walters EH,et al.Airway inflammation in chronic obstructive pulmonary disease(COPD):a true paradox[J].Expert Rev Respir Med,2017,11(10):827-839. [5]王嘉,孙武装,王鹏羽,等.慢性阻塞性肺疾病患者血清蛋白酶与抗蛋白酶的表达及意义[J].山东医药,2012,52(21):54-56. [6]付玥川,丁婕,邓炯.氧化应激在慢性阻塞性肺疾病发生中的作用及防治策略[J].国际呼吸杂志,2016,36(2):133-137. [7]许容容,解卫平.β2受体激动剂:用于治疗慢性阻塞性肺病的支气管舒张剂[J].药学进展,2016,40(5):363-369. [8]赵文丽.噻托溴铵和奥洛特罗复方获FDA批准用于维持治疗慢性阻塞性肺病[J].国际药学研究杂志,2015,42(4):472-472. [9]Cazzola M,Calzetta L,Barnes PJ,et al.Effica-cy and safety profile of xanthines in COPD:a network meta-analysis[J].Eur Respir Rev,2018,27(148):1-11. [10]王聪颖,张庆,张阳,等.戒烟干预联合沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病的疗效观察[J].广东医学,2014,35(7):1053-1055. [11]Rabe KF,Hurst JR,Suissa S.Cardiovascular dis-ease and COPD:dangerous liaisons[J].Eur Respir Rev,2018,27(149):57-89. [12]张秀丽,陈涵,程绩,等.长效抗胆碱药联合β2-受体激动剂治疗慢性阻塞性肺疾病急性加重期患者的临床观察[J].检验医学与临床,2018,15(5):708-711. [12]赵洪达,陈建波,许群,等.吸入糖皮质激素治疗稳定期COPD的疗效及对患者内皮功能及生活质量的影响[J].河北医学,2016,22(2):209-212. [13]戢太兵,艾红艳,秦永刚,等.吸入糖皮质激素辅助常规抗炎治疗稳定期COPD的价值分析[J].中外医学研究,2019(4):6-8. [14]刘巍,王晓兵,宋志军.特布他林和糖皮质激素联合用药治疗COPD急性加重期的临床研究[J].河北医药,2015,21(17):2665-2666. [15]屈磊,龚传明,章涛,等.孟鲁司特钠对COPD急性发作患者肺功能及炎性介质的影响[J].西南国防医药,2015,25(10):1058-1061. [16]秦艳.孟鲁司特钠治疗慢性阻塞性肺疾病122例临床疗效观察[J].国际呼吸杂志,2016,36(9):658-661. [17]董苗.罗氟司特治疗稳定期COPD疗效与安全性的系统评价[D].重庆医科大学,2016. [18]顾艳利,代冰,康健.罗氟司特治疗稳定期慢性阻塞性肺疾病的疗效及其安全性的Meta分析[J].中华危重症医学杂志(电子版),2016,9(3):174-183. [19]严德斌,杨志明,孙炜佳.N-乙酰半胱氨酸对COPD患者血清炎性因子、免疫功能及肺功能的影响[J].海南医学院学报,2015,21(12):1627-1629. [20]赵晓风.N-乙酰半胱氨酸辅助治疗对稳定期COPD患者气道炎症、重塑等的调节作用[J].海南医学院学报,2016,22(12):1250-1253. [21]Miravitlles M,Anzueto A.Antibiotic prophylaxis in COPD:Why,when,and for whom[J].Pulm Pharmacol Ther,2015(32):119-123. [22]魏洋亿.大环内酯类药物预防慢性阻塞性肺疾病急性发作的Meta分析[J].国外医药(抗生素分册),2019,40(2):73-83. [23]薛守斌,刘巍,吴允萍,等.大环内酯类抗生素在慢性阻塞性肺疾病中的免疫调节作用[J].临床内科杂志,2018,35(3):213-215. [24]刘旭东,吴俊丽,刘云,等.辛伐他汀联合阿奇霉素治疗老年慢性阻塞性肺疾病合并肺动脉高压患者的疗效[J].实用医学杂志,2016,32(7):1199-1200. [25]Lyon C,Colangelo H,Desanto K.Antibiotic Prophylaxis for COPD Exacerbations[J].Am Fam Physician,2018,97(8):527-528.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Medical Information,2018,31(02):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(02):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]罗会义.脑梗死抑郁的发作因素及临床治疗研究[J].医学信息,2018,31(04):181.[doi:10.3969/j.issn.1006-1959.2018.04.069]
　LUO Hui-yi.A Study on the Attack Factors and Clinical Treatment of Depression in Cerebral Infarction[J].Medical Information,2018,31(02):181.[doi:10.3969/j.issn.1006-1959.2018.04.069]
[6]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[7]吕桂英.影响糖尿病患者药物治疗依从性相关因素临床分析[J].医学信息,2018,31(08):109.[doi:10.3969/j.issn.1006-1959.2018.08.036]
　LV Gui-ying.Clinical Analysis of Factors Related to Compliance with Drug Therapy in Patients with Diabetes Mellitus[J].Medical Information,2018,31(02):109.[doi:10.3969/j.issn.1006-1959.2018.08.036]
[8]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Medical Information,2018,31(02):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[9]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(02):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[10]王煜婷.原发性痛经发病机制及口服药物治疗进展[J].医学信息,2018,31(13):56.[doi:10.3969/j.issn.1006-1959.2018.13.016]
　WANG Yu-ting.Research Progress in Pathogenesis and Oral Medication of Primary Dysmenorrhea[J].Medical Information,2018,31(02):56.[doi:10.3969/j.issn.1006-1959.2018.13.016]

更新日期/Last Update: 2020-01-15